The Advisory Board Company Reports Fiscal Year 2010 Second Quart...($17730 ...),Health

Date:11/2/2009

$17,730 ------ ------ ------- ------- Three Months Ended Six Months Ended September 30, September 30, 2009 2008 2009 2008 ---- ---- ---- ---- Net (loss) income $(2,116) $5,403 $2,072 $11,733 Write-off of capitalized software, net of tax 4,860 - 4,860 - Option cancellation charge, net of tax 1,273 - 1,273 - ----- --- ----- --- Adjusted net income $4,017 $5,403 $8,205 $11,733 ------ ------ ------ ------- Three Months Ended Six Months Ended September 30, September 30, 2009 2008 2009 2008 ---- ---- ---- ---- GAAP (loss) earnings per diluted share $(0.14) $0.32 $0.13 $0.68 Write-off of capitalized software, net of tax 0.32 - 0.32 - Option cancellation charge, net of tax 0.08 - 0.08 - ---- --- ---- --- Adjusted earnings per diluted share $0.26 $0.32 $0.53 $0.68 ----- ----- ----- ----- (1) Other income, net includes interest income of $0.6 million and $0.9 million for the three months ending September 30, 2009 and 2008, respectively, and $1.2 mil
'/>"/>

SOURCE The Advisory Board Company Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
Related medicine news :

1. Important new novel 2009 H1N1 flu advisory for cardiopulmonary transplantation
2. The Advisory Board Company Schedules Second Quarter Conference Call for November 2, 2009
3. Bionovo Adds Dr. Debu Tripathy to Their Medical Advisory Board
4. World-first mental health media initiative announces inaugural Advisory Group
5. Tranziger Announces Formation of Global Advisory & Development Team
6. FDA Advisory Committee Recommends Approval of PEGINTRON(R) for the Adjuvant Treatment of Stage III Malignant Melanoma
7. William Fuchs Named to PerfectServe Advisory Board
8. Data Strategy Invited to Become a Member of VMware's Partner Technical Advisory Board (PTAB)
9. Star Scientific Breaks New Ground, Plans FDA Filing for Approval of First Modified Risk Tobacco Product; Nominates Curtis Wright, MD, MPH for FDA Advisory Committee
10. FDA Advisory Committee Unanimously Recommends Approval of XIAFLEX(TM) for Treatment of Dupuytrens Disease
11. Robert Fanning Named to PerfectServe Advisory Board